All In Biotech

Drug Trial Radar · NCT04868604

64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer

Last checked: Nov 20, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

54

Planned (sponsor's estimate)

Start

Aug 11, 2021

Primary completion

Sep 2026

Study completion Sep 2026

Sponsor

Lead sponsor
Clarity Pharmaceuticals LtdIndustry
Sponsor type
Industry
First posted
May 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.

Conditions

  • Prostatic Neoplasms, Castration-Resistant

Interventions

  • 64Cu-SAR-bisPSMADrug

    64Cu-SAR-bisPSMA

  • 67Cu-SAR-bisPSMADrug

    67Cu-SAR-bisPSMA

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Biodistribution of 64Cu-SAR-bisPSMATime frame: 48 hours
  2. Dosimetry of 64Cu-SAR-bisPSMATime frame: 48 hours
  3. Modelling of 67Cu-SAR-bisPSMA dosimetry utilizing the 64Cu-SAR-bisPSMA PET/CT scansTime frame: 48 hours
  4. Maximum Tolerated Dose (MTD) or Maximum Feasible Dose of a single dose of 67Cu-SAR-bisPSMATime frame: 8 weeks
  5. Recommended dose of two doses of 67Cu-SAR-bisPSMATime frame: 14 weeks
  6. Efficacy of 67Cu-SAR-bisPSMA in terms of Prostate specific Antigen (PSA) responseTime frame: Up to 5 years
  7. Efficacy of 67Cu-SAR-bisPSMA in terms of radiographic responseTime frame: Up to 5 years
  8. Incidence of 67Cu-SAR-bisPSMA Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: Up to 5 years
  9. Safety and tolerability of 67Cu-SAR-bisPSMA: Number of Participants With Changes from baseline in Vital SignsTime frame: Up to 1 year
  10. Safety and tolerability of 67Cu-SAR-bisPSMA: Number of Participants With Changes from baseline in electrocardiogram (ECG) parametersTime frame: Up to 24 weeks
  11. Safety and tolerability of 67Cu-SAR-bisPSMA: Number of Participants With Changes from baseline in laboratory resultsTime frame: Up to 22 weeks
  12. Incidence of 64Cu-SAR-bisPSMA Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: Up to 5 years

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Stanford Cancer Institute

    Stanford, California · Recruiting

  • East Jefferson General Hospital

    River Ridge, Louisiana · Recruiting

  • BAMF Health

    Grand Rapids, Michigan · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Washington University School of Medicine at Barnes-Jewish Hospital

    St Louis, Missouri · Recruiting

  • XCancer

    Omaha, Nebraska · Recruiting

  • Weill Cornell Medicine at New York-Presbyterian

    New York, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.